Diabetes, Vol 47, Issue 1 93-97, Copyright © 1998 by American Diabetes Association

ARTICLES

Hypoglycemia overrides amylin-mediated regulation of gastric emptying in rats

BR Gedulin and AA Young
Amylin Pharmaceuticals, San Diego, California 92121, USA.

Amylin, a 37-amino acid peptide hormone co-secreted with insulin, potently governs the rate of gastric emptying. Hypoglycemia, in the absence of agents such as amylin, is reported to accelerate gastric emptying. We asked whether hypoglycemia had a similar action on gastric emptying in the presence of amylin. In preliminary experiments using a phenol red gavage technique in fasted SD rats, we showed that insulin administration accelerated gastric emptying in a dosage-dependent manner. This acceleration was totally prevented by coadministration of glucose in dosages that prevented a change in plasma glucose, indicating that insulin per se did not affect gastric emptying. The effect on gastric emptying of hypoglycemia induced by a 5 mU/min insulin infusion (t = 5-90 min) was assessed in conscious rats continuously infused with amylin (50 pmol x kg-1 x min-1; t = -30 to 90 min). Gastric emptying was indicated by the appearance in plasma of label from 3-O-methyl-[3H]glucose gavaged at t = 0 min. Label appearance was markedly inhibited in rats preinfused with amylin (84% reduced vs. saline controls at t = 30 min), indicating amylin inhibition of gastric emptying. In amylin-treated rats that were subsequently infused with insulin, gavaged label abruptly appeared in plasma when plasma glucose had fallen to 2.1 +/- 0.1 mmol/l (at t approximately 45 min), consistent with a reversal by hypoglycemia of amylin's inhibition of gastric emptying. These data support the idea of a central "fail-safe" mechanism whereby hypoglycemia can override the slowing of gastric emptying by amylin.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				O. Schmitz, B. Brock, and J. Rungby Amylin Agonists: A Novel Approach in the Treatment of Diabetes Diabetes, December 1, 2004; 53(suppl_3): S233 - S238. [Abstract] [Full Text] [PDF]

				J. B. Buse, C. Weyer, and D. G. Maggs Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy Clin. Diabetes, July 1, 2002; 20(3): 137 - 144. [Abstract] [Full Text] [PDF]

				F. Whitehouse, D. F. Kruger, M. Fineman, L. Shen, J. A. Ruggles, D. G. Maggs, C. Weyer, and O. G. Kolterman A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes Diabetes Care, April 1, 2002; 25(4): 724 - 730. [Abstract] [Full Text] [PDF]

				M.R. Davids, Y. Edoute, S. Stock, and M.L. Halperin Severe degree of hyperglycaemia: insights from integrative physiology QJM, February 1, 2002; 95(2): 113 - 124. [Abstract] [Full Text] [PDF]

				J.-M. Ye, M. Lim-Fraser, G. J. Cooney, G. J. S. Cooper, M. A. Iglesias, D. G. Watson, B. Choong, and E. W. Kraegen Evidence that amylin stimulates lipolysis in vivo: a possible mediator of induced insulin resistance Am J Physiol Endocrinol Metab, April 1, 2001; 280(4): E562 - E569. [Abstract] [Full Text] [PDF]

				R. D. Reidelberger, U. Arnelo, L. Granqvist, and J. Permert Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats Am J Physiol Regulatory Integrative Comp Physiol, March 1, 2001; 280(3): R605 - R611. [Abstract] [Full Text] [PDF]